Tyrosine kinase receptors

Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

Retrieved on: 
Monday, March 29, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Cancer, Breakthrough therapy, Orphan drugs, Hepatology, Tyrosine kinase receptors, Pemigatinib, Cholangiocarcinoma, Fibroblast growth factor receptor 2, FIGHT-202, FIGHT, Pemazyre® (pemigatinib), Incyte

Pemazyre offers a much-needed option to eligible patients that have only had few effective treatment options until today.

Key Points: 
  • Pemazyre offers a much-needed option to eligible patients that have only had few effective treatment options until today.
  • Historically, patients living with advanced cholangiocarcinoma have had very limited treatment options, said Helen Morement, CEO, AMMF The Cholangiocarcinoma Charity.
  • FIGHT-302 is a Phase 3 study investigating Pemazyre as a first-line treatment for patients with cholangiocarcinoma with FGFR2 fusions or rearrangements.
  • In Europe, Pemazyre is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors

Retrieved on: 
Wednesday, March 24, 2021
Sortilin 1, Tyrosine kinase inhibitor, Tyrosine kinase, Tyrosine kinase receptors

Targeting the sortilin receptor is an exciting and promising new approach for the potential treatment of cancer.

Key Points: 
  • Targeting the sortilin receptor is an exciting and promising new approach for the potential treatment of cancer.
  • The U.S. Food and Drug Administration (FDA) recently granted fast track designation to TH1902 as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy.
  • TH1902 is the Companys lead PDC stemming from Theratechnologies SORT1+ Technology in oncology.
  • Commercially available anticancer drugs, like docetaxel, doxorubicin or tyrosine kinase inhibitors are conjugated to Theratechnologies investigational novel peptide to specifically target sortilin receptors.

Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)

Retrieved on: 
Wednesday, March 24, 2021
Tyrosine kinase receptors, Clusters of differentiation, Fibroblast growth factor receptor 2

The interim analysis of cohort 2 is based on 14 evaluable patients who had at least one post-baseline tumor assessment.

Key Points: 
  • The interim analysis of cohort 2 is based on 14 evaluable patients who had at least one post-baseline tumor assessment.
  • The positive interim analysis allows the study to advance to its next stage and enrol a total of 43 patients.
  • Dr. Marc Engelhardt, Chief Medical Officer, said: We are very pleased with the positive interim results for this cohort of iCCA patients with FGFR2 gene mutations or amplifications.
  • The clinical benefit with derazantinib is similar to that reported for iCCA patients with FGFR2 gene fusions earlier this year.

Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, March 23, 2021
Tyrosine kinase receptors, ROS1, Anaplastic lymphoma kinase, Protein kinase inhibitor, Non-small-cell lung carcinoma, Branches of biology, Clinical medicine, Targeted therapy, Medicine, ALK inhibitor

CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christopher Turner, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ --Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christopher Turner, M.D., as Chief Medical Officer.
  • "Chris is a dedicated physician and drug developer who has guided the early development, global registration studies, and marketing approval of multiple kinase inhibitor therapies for patients with cancer," said James Porter, Ph.D., Chief Executive Officer of Nuvalent.
  • "I am delighted to welcome him to the Nuvalent team, where his clinical vision and proven leadership will help drive the progression of our robust pipeline through multiple near-term clinical milestones."
  • Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Tyrosine kinase receptors, Clusters of differentiation, Protein kinase inhibitors, Anaplastic lymphoma kinase, Colony stimulating factor 1 receptor, ALK inhibitor

For MET/SRC/CSF1R inhibitor, TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.

Key Points: 
  • For MET/SRC/CSF1R inhibitor, TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.
  • For its newest drug candidate, ALK-inhibitor TPX-0131, Turning Point will present preclinical potency data against ALK resistance mutations and in-vivo data demonstrating brain tissue penetration.
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics drug candidates, the results, conduct, progress and timing of Turning Point Therapeutics pre-clinical studies and plans regarding future development activities.

Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Tyrosine kinase receptors, Enzymes, Receptor tyrosine kinase, ErbB, Kinase, Tyrosine kinase, Epidermal growth factor receptor, Protein kinase

Both presentations will also be available online on the Companys website at https://www.blackdiamondtherapeutics.com/technology/presentations-public... .

Key Points: 
  • Both presentations will also be available online on the Companys website at https://www.blackdiamondtherapeutics.com/technology/presentations-public... .
  • The ErbB receptors are a group of receptor tyrosine kinases involved in key cellular functions, including cell growth and survival.
  • Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting

Retrieved on: 
Wednesday, March 10, 2021
Branches of biology, Medical specialties, Immunology, Medicine, Tyrosine kinase receptors, Cancer treatments, Neurotrophic factors, HER2/neu, Monoclonal antibody therapy, Neuregulin 1, Antibody, ERBB3

All e-posters will be available on this website from Saturday, April 10 to Monday, June 21, 2021.

Key Points: 
  • All e-posters will be available on this website from Saturday, April 10 to Monday, June 21, 2021.
  • The posters will also be available on the Merus website as of Saturday, April 10, 2021.
  • In preclinical studies, Zeno also potently inhibits HER2/HER3 heterodimer formation and tumor growth in models harboring NRG1 fusions.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics .

Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Wednesday, March 10, 2021
Cancer, Melanoma, American Association for Cancer Research, Medicine, Causes of death, Health, Tyrosine kinase receptors

London, UK 10 March 2021 Achilles Therapeutics plc (Achilles or the Company), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at theAmerican Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021.

Key Points: 
  • London, UK 10 March 2021 Achilles Therapeutics plc (Achilles or the Company), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at theAmerican Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021.
  • Details of the abstract and poster presentation are as follows:
    The abstract and full session details can be found atwww.aacr.org.
  • Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.
  • The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma.

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

Retrieved on: 
Tuesday, March 9, 2021
Chemical compounds, Chemistry, Organic compounds, Piperidines, Breakthrough therapy, Protein kinase inhibitors, Ceritinib, Tyrosine kinase receptors, Crizotinib, Alectinib, Anaplastic lymphoma kinase, Lorlatinib

The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.

Key Points: 
  • The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.
  • "It is essential that we identify patients with this cancer biomarker quickly and accurately so they can be treated with effective targeted therapy.
  • The VENTANA ALK (D5F3) CDx Assay is now FDA approved as a companion diagnostic in four targeted treatments - XALKORI (crizotinib), ZYKADIA (ceritinib), ALECENSA (alectinib) and LORBRENA (lorlatinib).
  • It is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib), ZYKADIA (ceritinib), ALECENSA (alectinib) or LORBRENA (lorlatinib) in the US.

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

Retrieved on: 
Tuesday, March 9, 2021
Chemical compounds, Chemistry, Organic compounds, Piperidines, Breakthrough therapy, Protein kinase inhibitors, Ceritinib, Tyrosine kinase receptors, Crizotinib, Alectinib, Anaplastic lymphoma kinase, Lorlatinib

The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.

Key Points: 
  • The VENTANA ALK (D5F3) CDx Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for LORBRENA.
  • "It is essential that we identify patients with this cancer biomarker quickly and accurately so they can be treated with effective targeted therapy.
  • The VENTANA ALK (D5F3) CDx Assay is now FDA approved as a companion diagnostic in four targeted treatments - XALKORI (crizotinib), ZYKADIA (ceritinib), ALECENSA (alectinib) and LORBRENA (lorlatinib).
  • It is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib), ZYKADIA (ceritinib), ALECENSA (alectinib) or LORBRENA (lorlatinib) in the US.